Budesonide Inhalation Suspension: A Review of its Use in Infants, Children and Adults with Inflammatory Respiratory Disorders

Hvizdos, K.M.; Jarvis, B.
November 2000
Drugs;Nov2000, Vol. 60 Issue 5, p1141
Academic Journal
Budesonide, a topically active corticosteroid, has a broad spectrum of clinically significant local anti-inflammatory effects in patients with inflammatory lung diseases including persistent asthma. In infants and young children with persistent asthma, day- and night-time symptom scores, and the number of days in which β-agonist bronchodilators were required, were significantly lower during randomised, double-blind treatment with budesonide inhalation suspension 0.5 to 2 mg/day than placebo in 3 multicentre trials. Significantly fewer children discontinued therapy with budesonide inhalation suspension than with placebo because of worsening asthma symptoms in a study that included children who were receiving inhaled corticosteroids at baseline. Recent evidence indicates that budesonide inhalation suspension is significantly more effective than nebulised sodium cromoglycate in improving control of asthma in young children with persistent asthma. At a dosage of 2 mg/day, budesonide inhalation suspension significantly reduced the number of asthma exacerbations and requirements for systemic corticosteroids in preschool children with severe persistent asthma. In children with acute asthma or wheezing, the preparation was as effective as, or more effective than oral prednisolone in improving symptoms. In children with croup, single 2 or 4mg dosages of budesonide inhalation suspension were significantly more effective than placebo and as effective as oral dexamethasone 0.6 mg/kg or nebulised L-epinephrine (adrenaline) 4mg in alleviating croup symptoms and preventing or reducing the duration of hospitalisation. Early initiation of therapy with budesonide inhalation suspension 1 mg/day appears to reduce the need for mechanical ventilation and decrease overall corticosteroid usage in preterm very low birthweight infants at risk for chronic lung disease. In adults with persistent asthma, budesonide inhalation suspension ≤8 mg/day has been compared with inhaled budesonide 1.6 mg/day and fluticasone propionate 2 mg/day administered by metered dose inhaler. Greater improvements in asthma control occurred in patients during treatment with budesonide inhalation suspension than with budesonide via metered dose inhaler, whereas fluticasone propionate produced greater increases in morning peak expiratory flow rates than nebulised budesonide. Several small studies suggest that the preparation has an oral corticosteroid-sparing effect in adults with persistent asthma and that it may be as effective as oral corticosteroids during acute exacerbations of asthma or chronic obstructive pulmonary disease. The frequency of adverse events was similar in children receiving budesonide inhalation suspension 0.25 to 2 mg/day or placebo in 12-week studies. During treatment with budesonide inhalation suspension 0.5 to 1 mg/day in 3 nonblind 52-week studies, growth velocity in children was generally unaffected; however, a small but statistically significant decrease in growth velocity was detected in children who were not using inhaled corticosteroids prior to the introduction of budesonide inhalation suspension. Hypothalamic-pituitary-adrenal axis function was not affected by short (12 weeks) or long (52 weeks) term treatment with nebulised budesonide. In conclusion, budesonide inhalation suspension is the most widely available nebulised corticosteroid, and in the US is the only inhaled corticosteroid indicated in children aged ≥1 year with persistent asthma. The preparation is suitable for use in infants, children and adults with persistent asthma and in infants and children with croup.


Related Articles

  • Endoscopic Management of Severe Subglottic Stenosis in Wegener’s Granulomatosis. Stappaerts, I.; Van Laer, C.; Deschepper, K.; Van de Heyning, P.; Vermeire, P. // Clinical Rheumatology;Jul2000, Vol. 19 Issue 4, p315 

    : The optimal treatment for severe subglottic stenosis secondary to Wegener’s granulomatosis remains controversial. We report the case of a symptomatic middle-aged woman who was successfully treated with intratracheal dilation and intralesional injection of corticosteroids. The literature...

  • American Thoracic Society Intl Conference Long-term ICS use reduces pleural effusion in patients with CAP.  // Biomedical Market Newsletter;6/1/2012, Vol. 21, p1 

    The article focuses on a study according to which prior treatment with inhaled corticosteroids in patients with respiratory disorders who develop community acquired pneumonia (CAP) is associated with a lower incidence and severity of parapneumonic effusion.

  • Treatment of small airways involvement in asthma: clinical results. Usmani, Omar S. // Hot Topics in Respiratory Medicine;2013, Issue 23, p13 

    The small airways are currently a hot topic in the respiratory world. This airways region has long been known as the "quiet zone" of the lung, but a recent resurgence of interest by researchers using modified respiratory physiological techniques from the past and novel imaging modalities, has...

  • Preventing exacerbations in chronic obstructive pulmonary disease: tiotropium in long-term trials. Dusser, Daniel // Hot Topics in Respiratory Medicine;2011, Vol. 6 Issue 19, p19 

    Exacerbations are acute events that occur with increasing frequency and severity during the course of chronic obstructive pulmonary disease (COPD). Exacerbations induce long-lasting worsening consequences in patients with COPD and may contribute to the progression of the disease. Therefore,...

  • How effective are leukotriene inhibitors for asthma in children? Morden, Nancy E.; St. Anna, Leilani // Journal of Family Practice;Apr2004, Vol. 53 Issue 4, p325 

    explains that leukotrienes are potent mediators of inflammation and are believed to contribute significantly to the inflammatory pathophysiology of asthma. Leukotriene inhibitors interfere with leukotriene production or leukotriene receptors and thus inhibit inflammation. For children, the...

  • Insights into Early Treatment of Mild Asthma: Do Inhaled Corticosteroids Make a Difference? Tan, Wan C. // Pediatric Drugs;2007, Vol. 9 Issue 4, p219 

    Approaches to the management of moderate-to-severe persistent asthma in both children and adults are widely accepted but the treatment of mild persistent asthma remains controversial because of the lack of agreement on what constitutes mild asthma and whether regular treatment is required at...

  • Co-morbidity is the norm, not the exception: chronic respiratory diseases in chronic drug users. Kim, Theresa W.; Samet, Jeffrey H. // Primary Care Respiratory Journal;Dec2012, Vol. 21 Issue 4, p364 

    The article presents the author's opinion on a study on chronic respiratory diseases in chronic drug users. It mentions that the drug users have respiratory medications, primarily bronchodilators and inhaled corticosteroids. It states that the chronic, non-infectious respiratory diseases...

  • Ciclesonide a breath of fresh air in asthma. Salmon, Kimberley // PharmacoEconomics & Outcomes News;5/7/2005, Issue 477, p3 

    Asthma is a chronic respiratory disease that occurs commonly in developed countries. The disease is associated with substantial morbidity and costs, and often greatly affects the quality of life (QOL) of patients. Inhaled corticosteroids have been the mainstay of asthma therapy for some time and...

  • An Alternate Treatment for UVEITIS. S. A. // Arthritis Today;Jan/Feb2012, Vol. 26 Issue 1, p46 

    The article offers information on a study of time-released corticosteroids surgical implants, which can be used as an alternative for the traditional oral corticosteroids immunosuppressive drugs to treat uveitis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics